234 related articles for article (PubMed ID: 17208410)
1. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
Dutta S; Reed RC
Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
[TBL] [Abstract][Full Text] [Related]
2. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
Dutta S; Reed RC; O'Dea RF
Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
[TBL] [Abstract][Full Text] [Related]
3. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Reed RC; Cavanaugh JH
J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
[TBL] [Abstract][Full Text] [Related]
4. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
Reed RC; Dutta S; Liu W
Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Zhang Y; Lee LL; O'Dea R
Biopharm Drug Dispos; 2004 Nov; 25(8):353-7. PubMed ID: 15378556
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
Dutta S; Zhang Y
Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
[TBL] [Abstract][Full Text] [Related]
7. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
Dutta S; Reed RC
J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
[TBL] [Abstract][Full Text] [Related]
8. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
Reed RC; Dutta S
Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
10. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.
Garikipati V; Toops DS; Fang Q
Curr Med Res Opin; 2008 Jul; 24(7):1869-76. PubMed ID: 18593524
[TBL] [Abstract][Full Text] [Related]
12. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit.
Boggs JG; Preis K
Epilepsia; 2005 Jun; 46(6):949-51. PubMed ID: 15946337
[TBL] [Abstract][Full Text] [Related]
13. The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric-coated and extended release divalproex sodium formulations.
Ahmad AM; Douglas Boudinot F; Barr WH; Reed RC; Garnett WR
Biopharm Drug Dispos; 2005 Dec; 26(9):417-25. PubMed ID: 16216031
[TBL] [Abstract][Full Text] [Related]
14. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
[TBL] [Abstract][Full Text] [Related]
15. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder.
Winter HR; DeVane CL; Figueroa C; Ennis DJ; Hamer-Maansson JE; Davis PC; Smith MA
Hum Psychopharmacol; 2007 Oct; 22(7):469-76. PubMed ID: 17729385
[TBL] [Abstract][Full Text] [Related]
16. Divalproex-ER pharmacokinetics in older children and adolescents.
Dutta S; Zhang Y; Conway JM; Sallee FR; Biton V; Reed MD; Kearns GL
Pediatr Neurol; 2004 May; 30(5):330-7. PubMed ID: 15165635
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence in development of antiepileptic drugs.
Sommerville KW
Epilepsy Res; 2006 Jan; 68(1):82-5. PubMed ID: 16377144
[TBL] [Abstract][Full Text] [Related]
19. Investigation of low levels of plasma valproic acid concentration following simultaneous administration of sodium valproate and rizatriptan benzoate.
Hokama N; Hobara N; Kameya H; Ohshiro S; Hobara N; Sakanashi M
J Pharm Pharmacol; 2007 Mar; 59(3):383-6. PubMed ID: 17331341
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]